Your browser doesn't support javascript.
loading
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Synnott, Patricia G; McQueen, R Brett; Ollendorf, Daniel A; Campbell, Jonathan D; Pearson, Steven D.
Afiliación
  • Synnott PG; Institute for Clinical and Economic Review, Boston, Massachusetts.
  • McQueen RB; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
  • Ollendorf DA; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
  • Campbell JD; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
  • Pearson SD; Institute for Clinical and Economic Review, Boston, Massachusetts.
J Manag Care Spec Pharm ; 26(6): 782-785, 2020 Jun.
Article en En | MEDLINE | ID: mdl-32463783
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Aspirina / Ácido Eicosapentaenoico / Análisis Costo-Beneficio / Rivaroxabán Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Manag Care Spec Pharm Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Aspirina / Ácido Eicosapentaenoico / Análisis Costo-Beneficio / Rivaroxabán Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Manag Care Spec Pharm Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos